Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)

Inclusion criteria

• Healthy volunteers
• Caucasian
• Resting heart rate ≥70 bpm (mean of 3 measures after 15 minutes of rest)
• No significant EKG abnormality
• No significant biological abnormalities at inclusion
• Healthy volunteers able to read and understand information letter and to give written informed consent
• Healthy volunteers with medical insurance
• Contraception for two months for women of childbearing age (Estrogen contraceptive or intrauterine device or tubal ligation) (NB : women with amenorrhea for more than 2 years will be considered postmenopausal)

Exclusion criteria

• Subjects who don't understand french language
• Person deprived of liberty by an administrative or judicial decision or protected adult subject (under guardianship)
• Pregnant women, nursing mother or women without contraception
• Healthy volunteers who participate to an other trial / participated to an other trial without drugs during the last month or a trial with drugs during the last 3 months
• Hypersensitivity to the active substance or to any of the excipients
• Congenital galactosemia, lactase deficiency, or glucose-galactose malabsorption
• Body mass index (BMI) < 18 kg/m² or > 30 kg/m²
• Severe hypotension (< 90/50 mmHg) (3 measures after 15 minutes of rest)
• Essential or secondary Hypertension (SBP ≥140 mmHg and/or DBP ≥90 mmHg) (3 measures after 15 minutes of rest)
• Active smoking at the day of inclusion (>5 cigarettes/day)
• Severe hypercholesterolemia (Total cholesterol >2,5 g/L)
• Practice sports intensively (≥ 1 hour/day)
• Renal insufficiency (creatinine clearance ≤ 60 ml/min/1,73 m² Cockroft and Gault formula)
• Known liver failure
• Known heart failure or suspected heart failure (congestive episode)
• Atrial fibrillation
• High-grade conduction block (Sick sinus syndrome, sino-atrial block or grade 2 or 3 atrio-ventricular block)
• Abnormal corrected QT with Bazett formula (cQT > 450 ms (men) or > 470 ms (women)).
• Pacemaker
• All cardiac or extra cardiac diseases, active or with sequelae, which, in the opinion of the investigator, is accompanied by a risk of cardiac or vascular consequences
• Retinal disease
• Taking any medication is prohibited during the study except oral contraceptive, acetaminophene or decision of the investigator. In addition, the administration of drugs listed in schedule 2 during the previous 4 weeks prohibits inclusion.